Abstract
Prostaglandins (PGs) of the J2 family including PGJ2, Δ12-PGJ2, and 15-deoxy-Δ12,14- PGJ2 (15d-PGJ2) are naturally occurring metabolites of PGD2. Among them, 15d-PGJ2 is a powerful ligand for the peroxisome proliferator-activated receptor-γ (PPARγ). 15d-PGJ2 and synthetic PPARγ ligands have been reported to exert several effects on vascular cells, such as antiproliferative, differentiation-inducing, anti-apoptotic, and anti-inflammatory effects, most of which seem to be atheroprotective, although PPARγ-independent mechanisms may be involved. Vascular endothelial cells, intimal smooth muscle cells, and cardiomyocytes express lipocalintype PGD synthase (L-PGDS) in vivo, which catalyzes the isomeric conversion of PGH2 to PGD2. L-PGDS expression in endothelial cells is stimulated by laminar fluid shear stress. PGD2 and 15d-PGJ2 are detected in the culture medium of endothelial cells exposed to shear stress. Serum and urinary levels of L-PGDS increase in diseases with vascular injuries, such as hypertension and diabetes. Based on these findings, we hypothesize that PGs of the J2 series are physiological substances produced in the vascular wall to protect vascular cells from injurious stimuli and to repress inflammatory reactions. If this hypothesis is correct, PGJ2 family members or other similar substances may provide novel preventive and therapeutic strategies for the treatment of vascular diseases.
Keywords: Prostaglandin, L-PGDS
Current Vascular Pharmacology
Title: Prostaglandin J2 Family and the Cardiovascular System
Volume: 2 Issue: 2
Author(s): Toshiyuki Sasaguri and Yoshikazu Miwa
Affiliation:
Keywords: Prostaglandin, L-PGDS
Abstract: Prostaglandins (PGs) of the J2 family including PGJ2, Δ12-PGJ2, and 15-deoxy-Δ12,14- PGJ2 (15d-PGJ2) are naturally occurring metabolites of PGD2. Among them, 15d-PGJ2 is a powerful ligand for the peroxisome proliferator-activated receptor-γ (PPARγ). 15d-PGJ2 and synthetic PPARγ ligands have been reported to exert several effects on vascular cells, such as antiproliferative, differentiation-inducing, anti-apoptotic, and anti-inflammatory effects, most of which seem to be atheroprotective, although PPARγ-independent mechanisms may be involved. Vascular endothelial cells, intimal smooth muscle cells, and cardiomyocytes express lipocalintype PGD synthase (L-PGDS) in vivo, which catalyzes the isomeric conversion of PGH2 to PGD2. L-PGDS expression in endothelial cells is stimulated by laminar fluid shear stress. PGD2 and 15d-PGJ2 are detected in the culture medium of endothelial cells exposed to shear stress. Serum and urinary levels of L-PGDS increase in diseases with vascular injuries, such as hypertension and diabetes. Based on these findings, we hypothesize that PGs of the J2 series are physiological substances produced in the vascular wall to protect vascular cells from injurious stimuli and to repress inflammatory reactions. If this hypothesis is correct, PGJ2 family members or other similar substances may provide novel preventive and therapeutic strategies for the treatment of vascular diseases.
Export Options
About this article
Cite this article as:
Sasaguri Toshiyuki and Miwa Yoshikazu, Prostaglandin J2 Family and the Cardiovascular System, Current Vascular Pharmacology 2004; 2 (2) . https://dx.doi.org/10.2174/1570161043476384
DOI https://dx.doi.org/10.2174/1570161043476384 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Signaling Through Rho GTPase Pathway as Viable Drug Target
Current Medicinal Chemistry Inflammation in Ischemic Stroke: Mechanisms, Consequences and Possible Drug Targets
CNS & Neurological Disorders - Drug Targets Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text
Current Vascular Pharmacology Emerging P2Y12 Receptor Antagonists: Role in Coronary Artery Disease
Current Vascular Pharmacology Role of Lysophosphatidylcholine (LPC) in Atherosclerosis
Current Medicinal Chemistry Characterization of Pharmaceutical IgG and Biosimilars Using Miniaturized Platforms and LC-MS/MS
Current Pharmaceutical Biotechnology Novel Treatment Strategies for the Nervous System: Circadian Clock Genes, Non-coding RNAs, and Forkhead Transcription Factors
Current Neurovascular Research Pharmacology of Appetite Suppression: Implication for the Treatment of Obesity
Current Drug Targets Cervical Cancer Diagnosis: Insights into Biochemical Biomarkers and Imaging Techniques
Combinatorial Chemistry & High Throughput Screening Is Hypertension an Inflammatory Process?
Current Pharmaceutical Design Contribution of Mast Cells to Cerebral Aneurysm Formation
Current Neurovascular Research Milestones in Antihypertensive Drug Treatment
Current Pharmaceutical Design Kinin Receptors in Vascular Biology and Pathology
Current Vascular Pharmacology Heart Failure in North America
Current Cardiology Reviews Circulating Endothelial Cells: Markers and Mediators of Vascular Damage
Current Stem Cell Research & Therapy Multi-Targeted Natural Products Evaluation Based on Biological Activity Prediction with PASS
Current Pharmaceutical Design Acute Phase Treatment of Pulmonary Embolism
Current Vascular Pharmacology Peptide and Non-peptide Antagonists Targeting Endothelin Receptors in Physiology and Pathology
Current Pharmaceutical Design Body Weight – The Importance of Getting it Right ‘Before’ Becoming Pregnant
Current Nutrition & Food Science Macrophage Activation in Atherosclerosis: Pathogenesis and Pharmacology of Plaque Rupture
Current Vascular Pharmacology